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with anti-PDL1 antibody-treated APCs. According to these 
results, we conclude that the co-administration of anti-
PDL1 antibody and alpha-galactosylceramide (αGalCer)-
pulsed APCs enhances iNKT cell-mediated antitumor 
immunity.
Keywords Invariant NKT cells · Anti-PDL1 antibody · 
PD-1 · Antitumor immunity
Abbreviations
AHR  Airway hypersensitivity reaction
APC  Allophycocyanin
APC/Cy7  Allophycocyanin/cyanin 7
αGalCer  Alpha-galactosylceramide
iNKT cells  Invariant natural killer T cells
NSCLC  Non-small cell lung cancer
PDL  Programmed death ligand
Th  Helper T cell
Introduction
Invariant natural killer T (iNKT) cells are innate-like 
immune cells, characterized by their invariant T cell 
receptor. They respond to glycolipid antigens, such as 
α-galactosylceramide (αGalCer), presented by the HLA 
class I-like molecule CD1d, and rapidly produce sub-
stantial amounts of cytokines upon stimulation [1]. iNKT 
cells play an important role in antitumor immunity via the 
activation of antigen-presenting cells (APCs), T cells, and 
natural killer (NK) cells as well as displaying direct cyto-
toxic functions toward cancer cells [2–4]. It is reported that 
the number of iNKT cells in the peripheral blood decreases 
and that proliferation in response to its ligand is impaired 
in cancer patients [5, 6]. Translational research aimed at 
Abstract The role of invariant natural killer T (iNKT) 
cells in antitumor immunity has been studied extensively, 
and clinical trials in patients with advanced cancer have 
revealed a prolonged survival in some cases. In recent 
years, humanized blocking antibodies against co-stimu-
latory molecules such as PD-1 have been developed. The 
enhancement of T cell function is reported to improve 
antitumor immunity, leading to positive clinical effects. 
However, there are limited data on the role of PD-1/pro-
grammed death ligand (PDL) molecules in human iNKT 
cells. In this study, we investigated the interaction between 
PD-1 on iNKT cells and PDL on antigen-presenting cells 
(APCs) in the context of iNKT cell stimulation. The block-
ade of PDL1 at the time of stimulation resulted in increased 
release of helper T cell (Th) 1 cytokines from iNKT cells, 
leading to the activation of NK cells. The direct antitumor 
function of iNKT cells was also enhanced after stimulation 
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manipulating the antitumor functions of iNKT cells is 
ongoing, and clinical benefits have been reported in some 
patients with non-small cell lung cancer (NSCLC) or head 
and neck cancer. The clinical benefits of the administration 
of αGalCer-pulsed APCs are especially seen in patients 
with improved cytokine production in response to its ligand 
following therapy. However, many patients with advanced 
cancer respond poorly to this therapy and the survival out-
comes of these patients remain poor [2, 7, 8]. This is, in 
part, attributed to the immunosuppressive tumor microen-
vironment that abrogates effective antitumor immunity, and 
strategies to overcome the immune suppression are needed 
to eradicate the tumor and improve the prognosis [9–12].
Programmed death-1 (PD-1) is a co-receptor that is 
expressed on activated lymphocytes. It is reported to 
regulate the function of activated T and B cells to induce 
peripheral tolerance, induce immunological memory, and 
prevent excess tissue damage in cases of infection [13]. Its 
ligands, PDL1 (B7-H1) and programmed death ligand 2 
(PDL2, B7-DC), are expressed on professional APCs and 
many tumor cells. PD-1/PDL interaction in the induction 
phase and effector phase of antitumor immunity is one of 
the mechanisms utilized by tumors to avoid T cell-medi-
ated rejection [14, 15]. Recent clinical trials of the sys-
temic administration of anti-PD-1 or anti-PDL1 antibody 
have shown objective and durable responses in patients 
with NSCLC, melanoma, and renal cell cancer [16, 17]. At 
the same time, severe adverse events have been reported, 
including adrenal insufficiency, myocarditis [16], pneumo-
nitis, and hepatitis [17].
There have been a few reports on the role of PD-1/PDL1 
in iNKT cells. In murine tumor models, the blockade of 
PD-1/PDL1 interaction led to enhanced interferon gamma 
(IFNγ) secretion and anti-metastatic activity of iNKT cells 
[18–20]. The function of PD-1/PDL on human iNKT cells 
has been poorly studied. The expression of PD-1 is reported 
to be elevated in the iNKT cells of tuberculosis and HIV 
patients. However, the reported impact of PD-1/PDL block-
ade on iNKT cell function differed among the studies [21–
23]. We therefore focused on the inhibitory effects of PD-1/
PDL interaction and assessed whether the blockade of this 
pathway could improve the antitumor responses of ligand-
activated iNKT cells. Results from our study showed 
that the surface expression of PD-1 was upregulated on 
activated human iNKT cells and blockade of PDL1 on 
αGalCer-pulsed APCs augmented Th1 cytokine production 
and direct cytotoxic function of iNKT cells. Furthermore, 
the upregulation of Th1 cytokines resulted in increased 
NK cell-mediated cytotoxicity. From these findings, we 
concluded that the administration of APCs that are prein-
cubated with anti-PDL1 antibodies would enhance iNKT 
cell-mediated antitumor immunity and provide the basis 
for new clinical studies on the administration of iNKT 




The human lung cancer cell line NCI-H460 [H460] 
(ATCC® HTB-177™) was purchased from American Type 
Culture Collection (ATCC). K562 cells were kindly pro-
vided by Dr. C. H. June [24]. Jurkat and A549 cells were 
kindly provided by Dr. K. Suzuki [25]. All cell lines were 
cultured in RPMI complete medium supplemented with 
10 % FBS and antibiotics.
Antibodies and reagents
Recombinant human IL-2 (Imunace; Shionogi, Osaka, 
Japan), recombinant human IFNγ (R&D), human GM-
CSF (GeneTech Co. Ltd, China) and α-galactosylceramide 
(αGalCer, KRN7000; REGiMMUNE, Tokyo, Japan) were 
used for cell culture and stimulation. For plate-bound 
assays, 96-well flat bottom culture plates were purchased 
from Greiner Bio-One. Recombinant soluble dimeric 
human CD1d:Ig fusion protein was purchased from BD 
Biosciences. Recombinant human PDL1 Fc chimera fusion 
protein and IgG1 Fc, and human anti-CD80 antibody (clone 
#37711) were purchased from R&D. Anti-human CD28 
antibody (clone 28.2) was purchased from BioLegend. For 
anti-PDL1 antibody removal, Dynabeads® M-280 Sheep 
anti-Mouse IgG was used together with DynaMag™-2 
Magnet (both were purchased from Novex and Life Tech-
nologies). Twelve-well plates with 0.4 μm polycarbonate 
membrane inserts (Corning) were used for the transwell 
assays.
FITC-conjugated anti-TCR Vα24 antibody (clone C15) 
and PE Vβ11 (clone C21) was purchased from Beckman 
Coulter. Functional grade and allophycocyanin (APC)-
conjugated anti-human PDL1 antibodies (clone 29E.2A3), 
anti-PDL2 (clone MIH18), APC anti-human PD-1 (clone 
EH12.EH7), PE anti-human PDL2 (clone 24F.10C12), 
anti-human CD80, APC/cyanin 7 (Cy7) anti-human CD3 
(clone HIT3a), and matching isotype controls were each 
purchased from BioLegend. PE anti-human CD3 (clone 
HIT3a), FITC anti-human CD56 (clone NCAM16.2) and 
APC anti-human CD56 were purchased from BD Pharmin-
gen. Biotin-SP-conjugated AffiniPure goat anti-mouse 
IgG,F(ab’)2 fragment-specific antibody was purchased from 
Jackson ImmunoResearch Laboratories and used together 
with APC streptavidin (BD Pharmingen) to assess block-
ing antibody binding in cultured cells. Peroxidase strepta-
vidin (Jackson ImmunoResearch) was used in an ELISA 
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to determine the concentration of anti-PDL1 antibodies. 
For cell purification, anti-FITC MicroBeads and the NK 
Cell isolation kit, CD56 microbeads, and CD3 microbeads 
were purchased from Miltenyi Biotec. Human IFNγ, IL-4, 
and TNFα ELISA sets (BD), the BD Cytometric Beads 
Array (CBA) System (BD), Bio-Plex Pro Human Cytokine 
27-Plex Panel (Bio-Rad), and the Milliplex MAP Human 
CD8+ T Cell Magnetic Bead Panel kit (Merck Millipore) 
were used for cytokine detection. Cytotoxicity assays were 
performed with the Cytotoxicity Detection KitPLUS (LDH) 
from Roche.
Collection of peripheral blood samples
Peripheral blood was obtained from healthy donors and 
NSCLC patients after obtaining their informed consent. All 
experiments were performed in accordance with the Decla-
ration of Helsinki and approved by our institutional review 
board (#1016).
Preparation of antigen‑presenting cells (APCs)
Peripheral blood mononuclear cells (PBMCs) were isolated 
via density gradient separation using Ficoll-Paque™ PLUS 
and cultured in RPMI 1640 complete medium with 100 
JRU/ml of IL-2 and 800 U/ml of GM-CSF, as previously 
described [26]. For the cytotoxicity assays and cytokine 
secretion assays, CD56-positive cells were depleted using 
the autoMACS® Pro Separator on day 0. A total of 200 ng/
ml of αGalCer was added on day 6, and all cultured cells 
were collected on day 7. The cultured cells underwent 
50 Gy of radiation before being added to the iNKT cell 
culture.
Induction of in vitro activated iNKT cells
PBMCs were cultured with antibody-treated αGalCer-
pulsed APCs and IL-2 for 7 days. On days 0 and 7, cells 
were counted and the percentage of Vα24+Vβ11+ cells 
and the rates of PD-1 and PDL1 positivity were assessed 
by flow cytometry using the FACSCanto™ II analyzer 
and FlowJo software program. For proliferation assays, 
the cells were restimulated on day 7 with antibody-treated 
αGalCer-pulsed APCs. On days 7 and 14, the number of 
iNKT cells was determined by multiplying the total cell 
count by the percentage of Vα24+Vβ11+ cells based on the 
flow cytometric data.
Preparation of αGalCer‑pulsed plate‑bound CD1d
Flat bottom 96-well plates were coated with 0.5 μg of 
CD1d dimeric protein with 2 μg of recombinant human 
PDL1 Fc chimera fusion protein or IgG1 Fc and 2 μg of 
anti-CD28 agonistic antibody in 30 μl PBS. After incuba-
tion for 6 h at 4 °C, 50 ng of αGalCer was added and the 
plate was incubated overnight at 37 °C. The next day, the 
wells were washed with PBS and incubated with cell cul-
ture medium before the addition of antibodies and NKT 
cells.
Cytokine secretion assay
Cultured iNKT cells were purified on day 7 via posi-
tive selection of Vα24-FITC-stained cells and cultured 
overnight in medium supplemented with 100 JRU/ml of 
IL-2. On day 8, the cells were collected and cultured in 
96-well plates. A total of 2 × 105 iNKT cells (1 × 105 in 
patients) were stimulated with plate-bound CD1d pulsed 
with αGalCer or 1 × 106 antibody-treated αGalCer-pulsed 
APCs. In the plate-bound assays, iNKT cells were treated 
with anti-PD-1 antibody, anti-CD80 antibody, or isotype 
control at 20 μg/ml prior to stimulation. The supernatants 
were collected after 24 h, and cytokine concentrations were 
assessed by ELISA. Multiplex cytokine assays were per-
formed with the Bio-Plex Pro Human Cytokine Assay kit. 
The Bio-Plex 3D system was used for the analysis.
Cytotoxicity assay
For the iNKT cell-mediated cytotoxicity assays, Vα24+ 
cells were positively selected on day 7, as described above. 
On day 8, the cells were counted and incubated with can-
cer cells at an E/T ratio of 5:1–15:1 in 96-well plates. Prior 
to co-culture, the cancer cells were suspended in medium 
and incubated for 30 min with 10 μg/ml of anti-PDL1 anti-
body or isotype-matched control. After 4 h of co-culture, 
cytotoxicity was assessed by measuring LDH release. The 
supernatants were collected, and the release of cytotoxic 
molecules was analyzed using the Milliplex MAP Human 
CD8+ T Cell Magnetic Bead Panel kit.
For NK-mediated cytotoxicity assays, the cells were 
purified using an NK Cell Isolation Kit, and NK cells were 
cultured for 24 h in supernatant obtained from αGalCer-
pulsed APC-restimulated iNKT cells. Prior to NK cell stim-
ulation, Sheep anti-Mouse IgG beads were applied to the 
supernatant, incubated for 30 min, and then magnetically 
removed together with the captured anti-PDL1 antibody 
or isotype control proteins. The cytokine concentrations in 
the supernatants were measured with the BD™ Cytometric 
Bead Array kit and FACS Verse analyzer. After 24 h, the 
NK cells were collected, counted, and co-cultured with 
cancer cells in 96-well plates at an E/T ratio of 2:1. The 
degree of cytotoxicity and levels of cytotoxic molecules 
were assessed as described above. In the assays with direct 
cell contact, NK cells were cultured for 24 h with NKT 
cells and αGalCer-pulsed APCs, after which they were 
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purified by the depletion of CD3 positive cells and positive 
selection with CD56 microbeads. The outcomes of stimula-
tion with soluble factors were compared to those of direct 
cell–cell contact using 0.4-μm-pore transwells with NK 
cells in the lower chamber and NKT cells plus αGalCer-
pulsed APCs in the upper chamber.
Statistical analysis
The statistical analysis was performed using the 
GraphPad PRISM® software program version 6.0b. 
Error bars represent the standard deviation in all 
graphs. p values of <0.05 were considered to be statis-
tically significant.
Results
PD‑1 expression on human iNKT cells
PBMCs were obtained from nine healthy donors and 18 
NSCLC patients. All patients were diagnosed with unre-
sectable advanced or recurrent NSCLC. Freshly iso-
lated healthy donor-derived peripheral blood iNKT cells 
expressed low levels of PD-1. In contrast, PD-1 expression 
on iNKT cells and T cells obtained from NSCLC patients 
was significantly higher than that observed in healthy vol-
unteers (Fig. 1a, b). Next, we evaluated the changes in 
PD-1 expression on in vitro activated iNKT cells derived 
from healthy donors. The percentage of PD-1 positive 
iNKT cells increased following stimulation with αGalCer 
(Fig. 1c, d). According to these results, we hypothesized 
that PD-1/PDL1 blockade on αGalCer-pulsed APCs at the 
time of iNKT cell stimulation could improve iNKT cell 
function.
Proliferative response of iNKT cells stimulated 
with PDL1 blocked APCs
To investigate the role of anti-PDL1 antibodies in the pro-
liferative responses of αGalCer-pulsed APC-stimulated 
iNKT cells, αGalCer-pulsed APCs were preincubated 
with anti-PDL1 or control antibody before addition to 
iNKT cell culture on days 0 and 7 (Fig. 2a). PDL1 was 
expressed on iNKT cells as well as on the APCs (Fig. 2b). 
Although the number of iNKT cells stimulated with anti-
PDL1 antibody-treated APCs tended to increase in both 
healthy donors and patients, the results differed widely 
among the donors with no significant differences between 
the two groups (Fig. 2c). The application of anti-PDL1 
antibodies could not reverse the impaired prolifera-
tive function found in the cancer patients to the level of 
healthy subjects.
Cytokine production of iNKT cells stimulated in the 
presence of PDL1
iNKT cells obtained from healthy donors were cultured 
with αGalCer and IL-2. On day 7, the cells were stained 
with anti-Vα24 FITC and positively selected via the 
autoMACS Pro Separator. The expression levels of CD80 
as well as PD-1 were upregulated in the cultured iNKT 
cells that were used in the assay (Fig. 3b).
Because PDL1 is reported to interact with both PD-1 and 
CD80 [27], the isolated cells were collected on day 8 and 
incubated with anti-PD-1 antibody, anti-CD80 antibody, 
both antibodies, or isotype control. αGalCer-pulsed CD1d 
and PDL1 fusion protein or IgG1 control protein pre-coated 
96-well plates were incubated with anti-PDL1 antibody or 
matching isotype control, and iNKT cells at 2 × 105 cells 
per well were seeded. The culture supernatants were col-
lected at 24 h, and the IFNγ concentration was measured 
with ELISA.
The stimulation of iNKT cells by recombinant human 
PDL1 fusion protein resulted in a decrease in the produc-
tion of IFNγ in comparison with the control protein. The 
blockade of PD-1 on iNKT cells resulted in a significant 
improvement in IFNγ release. The blockade of both PD-1 
and CD80 resulted in a threefold increase, while the block-
ade of PDL1 led to further enhancement (Fig. 3c). From 
these results, we concluded that the presence of PDL1 
fusion protein had a regulatory role on iNKT cell cytokine 
production through interactions with both PD-1 and CD80. 
There was also a minor but significant increase in the pro-
duction of cytokines in the control protein plus anti-PDL1 
antibody or anti-PD-1 plus CD80 groups, which may result 
from the interaction with the PDL1 expressed on the acti-
vated iNKT cells. Since the anti-PDL1 antibody used in 
the assay appeared to block interaction with both PD-1 and 
CD80, we mainly focused on the role of anti-PDL1 anti-
body in iNKT cell activation.
Cytokine production of iNKT cells with PDL1‑blocked 
APCs
We further evaluated the cytokine production of iNKT cells 
when stimulated with APCs as performed in clinical settings. 
iNKT cells obtained from healthy donors were cultured with 
antibody-treated APCs. On day 7, Vα24+ cells were purified 
as described above and restimulated on day 8 with matched 
APCs. The culture supernatant was collected after 24 h, and the 
cytokine concentrations were measured with ELISA. Results 
showed increased IFNγ and TNFα levels in the PDL1-blocked 
APC group, whereas there were no significant changes in the 
levels of IL-4 (Fig. 3d). Similar trends were observed with mul-
tiplex assays. IFNγ, TNFα, GM-CSF, and IL-2 levels tended to 
be increased in the PDL1-blocked APC group, whereas there 
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were no significant changes in the levels of IL-4, IL-13, IL-5, 
or IL-9 (Supplemental Fig. S1). These results indicate that 
blocking the PD-1/PDL1 interaction promotes Th1 cytokine 




































Fig. 1  PD-1 expression on human iNKT cells. a Representa-
tive FACS profiles of the PD-1 expression on Vα24+Vβ11+ iNKT 
cells obtained from healthy donors and patients. b The proportions 
of PD-1+ cells among Vα24+Vβ11+ iNKT cells and CD3+ T cells 
obtained from healthy donors (black circle) and patients (open cir-
cles) were determined by flow cytometry. The results are presented 
as the mean values with the distribution. *p < 0.05 (healthy controls 
vs. patients, unpaired t test). c, d PBMCs were obtained from eight 
healthy donors. Fresh PBMCs were stimulated with αGalCer-pulsed 
APCs with anti-PDL1 blocking antibody or isotype control anti-
body on day 0. c Representative profile of the PD-1 expression in 
Vα24+Vβ11+ iNKT cells before culture and 7 days after stimulation. 
d The proportions of PD-1+ cells among Vα24+Vβ11+ iNKT cells 
obtained from healthy donors before and 7 days after stimulation are 





















Fig. 2  Proliferation of human iNKT cells with PDL1 blockade. 
PBMCs were obtained from six healthy donors and eight non-small 
cell lung cancer patients. On day 0, PBMCs were stimulated with 
αGalCer-pulsed IL-2/GM-CSF cultured APCs with anti-PDL1 anti-
body or isotype control. On day 7, cells were collected and restimulated 
with PDL1-blocked or isotype control-treated APCs at a ratio of 1:2.5. 
The cells were collected and counted on day 14, and the proportion of 
Vα24+Vβ11+ iNKT cells was analyzed using flow cytometry. a Anti-
PDL1 antibody binding and PDL1 positivity on APCs were assessed 
using anti-mouse biotin plus streptavidin staining. b The percentage of 
PDL1-positive iNKT cells on days 0 and 7 were analyzed with APC-
conjugated anti-human PDL1. The gray-shaded histogram represents 
the isotype control; the unshaded histogram represents PDL1. c The 
number of Vα24+Vβ11+ iNKT cells on day 7 is shown. PDL1 positivity 
on APCs was analyzed according to the population comparison method 
using the FlowJo software program. P values were calculated using the 
unpaired t test. isotype, isotype control; aPDL1 ab, anti-PDL1 antibody




























































Fig. 3  Cytokine secretion of iNKT cells following restimulation. 
PBMCs obtained from healthy donors were stimulated on day 0 with 
αGalCer and IL-2. On day 7, Vα24-FITC-stained cells were purified 
by autoMACS Pro Separator positive selection. a The expanded cells 
were analyzed via FACS to determine the proportions of iNKT cells 
using anti-Vα24 and anti-Vβ11 antibodies. A representative result of 
assays performed with six donors (day 7 after MACS separation) is 
shown. b CD80 and Vα24 positivity in the purified iNKT cells used 
in the assay. c αGalCer-pulsed CD1d and recombinant human PDL1 
fusion protein or control protein-coated 96-well flat bottom plates 
with anti-CD28 agonistic antibody were used to stimulate the puri-
fied iNKT cells on day 8. Anti-PDL1 antibody, anti-PD-1 antibody, 
anti-CD80 antibody, or matched isotype control were added before 
stimulation. Culture supernatants were collected at 24 h, and cytokine 
concentration assays were performed by ELISA. Stimulations were 
performed in quadruplicates. Statistical analysis was performed 
using the unpaired t test. *p < 0.05. rhPDL1 Fc chimera, recombi-
nant human PDL1 Fc chimera fusion protein; rhIgG1, recombinant 
human IgG1. d Purified healthy donor-derived iNKT cells at 2 × 105 
cells were restimulated with 1 × 106 anti-PDL1 antibody or isotype 
control-treated APCs in 96-well plates. The culture supernatants were 
collected at 24 h, and ELISA of the cytokine concentrations were 
performed. Statistical analysis was performed using the paired t test. 
*p < 0.05. e A total of 1 × 105 purified iNKT cells obtained from 
advanced lung cancer patients were restimulated as described above 
with αGalCer or vehicle-pulsed APCs, preincubated with either anti-
PDL1 antibody or isotype control. The IFNγ concentration in the 
supernatants was analyzed as described above. A statistical analysis 
was performed using the unpaired t-test. *p < 0.05. isotype ctrl., iso-
type control; anti-PDL1, anti PDL1 antibody; anti-PD-1, anti-PD-1 
antibody; anti-CD80, anti-CD80 antibody; Veh-APC, vehicle-pulsed 
APC; αGalCer- APC, αGalCer-pulsed APC; Pt, patient
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secretion in activated iNKT cells. Since the lymphocytes from 
advanced cancer patients are reported to express multiple 
inhibitory factors [28], similar cytokine secretion assays were 
performed with iNKT cells derived from advanced lung can-
cer patients. Although the percentage and proliferation were 
extremely low in comparison with healthy donors, the iNKT 
cell purity was at 50–75 % after magnetic separation on day 7. 
IFNγ secretion was significantly increased to a level that was 
comparable to that in healthy donors, when anti-PDL1 antibod-
ies were applied (Fig. 3e).
Changes in the cytokine profiles with the addition 
of anti‑PDL2 antibody
Akbari et al. [29] previously reported that PDL2 regu-
lates Th2 cytokine production in mouse iNKT cells, 
which subsequently contributes to airway hypersensitiv-
ity. Because IL-2/GM-CSF-cultured APCs also expressed 
low levels of PDL2 in this study (Fig. 4a), we evaluated 
the potential of iNKT cells to produce various cytokines 
after stimulation with anti-PDL2 antibody-treated APCs. 
PDL2 blockade on APCs resulted in little increase in the 
Th1 cytokine levels compared to that observed in the 
PDL1-blocked APCs. On the other hand, IL-4 production 
tended to increase in the supernatants following anti-PDL2 
antibody-treated APC stimulation; however, it did not reach 
statistical significance (Fig. 4b, c).
iNKT cell‑mediated cytotoxicity toward tumor cell lines
Since direct cytotoxicity is one of the important functions 

















Fig. 4  The impact of PDL2 blockade on cytokine secretion by acti-
vated iNKT cells. Fresh PBMCs derived from healthy donors were 
stimulated as in Fig. 3. APCs were preincubated with anti-PDL2, 
anti-PDL1, or isotype control antibody before addition to the culture. 
iNKT cells were purified and restimulated as in Fig. 3, and the super-
natants were collected after 24 h. a PDL2 positivity and antibody 
binding on APCs were assessed as in Fig. 2a. The gray-shaded histo-
gram represents the isotype control, and the unshaded histogram rep-
resents PDL2. The IFNγ, IL-4, and TNFα concentrations were ana-
lyzed using ELISA. b Representative data for one healthy donor are 
presented. c The results of the comparison between PDL2-blocked 
and isotype control systems in four donors are shown. Statistical 
analyses were performed using the paired t test. isotype ctrl, isotype 
control; anti-PDL2, anti-PDL2 antibody
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antibodies in the direct cytotoxic activities of iNKT cells 
against several tumor cell lines, including lung cancer. The 
PDL1 and PDL2 expression levels in four tumor cell lines, 
including Jurkat, K562, A549 and H460, were analyzed by 
flow cytometry. PDL1 was expressed in all four cell lines. 
The expression of PDL1 was upregulated after IFNγ expo-
sure in the cancer cell lines (Fig. 5a). PDL2 expression 
was very low in all four cell lines, and the expression lev-
els increased in the two lung cancer cell lines with IFNγ. 
In order to assess whether PDL1 blockade would improve 
iNKT cell-mediated cytotoxicity, we cultured iNKT cells 
with anti-PDL1 antibody-treated APCs starting on day 
0 and performed 4-h cytotoxicity assays with purified 
iNKT cells on day 8. The iNKT cells stimulated with anti-
PDL1 antibody-treated APCs showed increased cytolysis 
of CD1d-negative lung cancer cell lines and K562 in two 
healthy donors (Fig. 5b). Similar experiments were per-
formed in three additional donors at E/T ratios of 5:1–15:1. 
Invariant NKT cells cultured with PDL1-blocked APCs 
displayed significantly increased cytolysis toward PDL1-
blocked lung cancer cell lines in comparison with the iso-
type controls (Fig. 5c). Multiplex assays of supernatants 
revealed increased levels of perforin and granzyme A from 
iNKT cells stimulated with anti-PDL1 antibody-treated 
APCs in healthy donor 4 (Fig. 5d). Similar trends were 
obtained in the samples obtained from healthy donor 1.
Adjuvant effects on NK cell‑mediated immunity 
via activated iNKT cells
Stimulation of iNKT cells with PDL1-blocked APCs 
resulted in the increased production of IL-2 and IFNγ. In 
order to examine whether soluble factors derived from acti-
vated iNKT cells could affect NK cell functions, we col-
lected iNKT cell culture supernatants and magnetically 
removed anti-PDL1 antibodies with Sheep anti-Mouse IgG. 
In the preliminary experiments, the residual antibody con-
centration was as low as 0.008 %. Isolated peripheral blood 
NK cells (Fig. 6a) were cultured in the supernatants for 
24 h, after which cytotoxicity assays against K562 and A549 
tumor cells were performed. The supernatant from iNKT 
cells stimulated with PDL1-blocked APCs had a positive 
impact on NK cell-mediated cytotoxicity compared to the 
isotype control-treated APCs (Fig. 6b). These findings may 
have been, in part, due to the increased degranulation of 
soluble molecules such as granzyme B (Fig. 6c). To further 
assess the effects of PDL1 blockade in a setting where acti-
vated iNKT cells had direct contact with NK cells, we cul-
tured iNKT cells and αGalCer-pulsed APCs together with 
purified NK cells at a ratio of 1:1:1 for 24 h. To compare the 
effects of soluble factors alone in this setting, we also cul-
tured the cells using a transwell system. The NK cells were 
purified from this system with the depletion of CD3-positive 
cells and the positive selection of CD56 positive cells via 
MACS. NK cells stimulated with direct cell contact dis-
played enhanced cytotoxicity toward A549 and K562 cells 
in comparison with soluble factors alone. In K562 cells, the 
blockade of PDL1 on APCs resulted in improved NK cell 
cytotoxicity when they were stimulated with either direct 
cell contact or soluble factors. Although similar trends were 
observed in the assays of the A549 cell lines, the results did 
not reach statistical significance (Fig. 6d).
Taken together, these results imply that blockade of 
PD-1/PDL1 interaction enhances the Th1 function of iNKT 
cells and augments both direct and indirect antitumor 
immunity.
Discussion
PD-1 was originally described as a receptor leading to 
apoptotic cell death of activated T cells [30]. From further 
research, PD-1 expression was found in activated T cells, B 
cells, NK cells, and NKT cells. PD-1 is reported to regulate 
the threshold, strength, duration, and properties of antigen-
specific immunological responses [13]. Tumors utilize this 
system to escape immunosurveillance. The expression of 
PDL1 on tumor cells induces T cell death, resulting in the 
evasion of host immunity [30]. PD-1 is now thought to reg-
ulate T cell functions through the inhibition of CD28-medi-
ated activation of phosphatidylinositol 3-kinase (PI3 K). 
PI3 K activation promotes cell survival and cytokine pro-
duction in T cells [31]. In NK cells, the PI3 K pathway is 
involved in target cell lysis and regulates perforin and gran-
zyme B mobilization and redistribution [32]. Moreover, in 
murine models, the interaction between PD-1 and PDL1 
has been shown to reduce the proliferation and production 
of cytokines such as IFNγ in iNKT cells.
In the current study, we found an elevated PD-1 expres-
sion in freshly isolated circulating iNKT cells in cancer 
patients, and this expression level increased after stimula-
tion with αGalCer, since PD-1 is expressed on activated 
lymphocytes. The high positivity of PD-1 in iNKT cells 
from cancer patients is thought to be due to prolonged stim-
ulation by tumor-derived ligands. To test the reversibility of 
anergy in these iNKT cells, we should perform cytotoxicity 
assays against autologous tumor cells. This was practically 
difficult due to the low frequency of iNKT cells in PBMCs 
and also because the amount of available tumor cells was 
insufficient.
The blockade of PD-1 on iNKT cells resulted in increased 
IFNγ secretion when stimulated in the presence of PDL1. 
The mechanism underlying this observation may include the 
blockade of PD-1-mediated inhibition of PI3 K, although 
the functions of CD28 on iNKT cells are considered to be 
slightly different from those in T cells [33]. In addition, we 
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Fig. 5  PDL1 expression in cancer cell lines and iNKT cell-mediated 
cytotoxicity. a Cancer cell lines were cultured for 24–48 h in RPMI1640 
complete medium alone or with 10 ng/ml of recombinant human IFNγ. 
PDL1 and PDL2 positivity was determined using flow cytometry. 
Shaded histograms: isotype control, dashed lines: medium only, bold 
lines: cultured with IFNγ. To test for cytotoxicity, iNKT cells were cul-
tured and purified as in Fig. 3. On day 8, iNKT cells were incubated 
with the tumor cell lines at an E/T ratio of 15:1 for 4 h. The percent 
cytotoxicity was determined based on the degree of LDH release 
according to the manufacturer’s protocol. The assays were performed in 
triplicate with cells obtained from two donors. b Representative values 
for two to four independent experiments for each donor. The error bars 
represent the standard deviation. P values were calculated using multi-
ple t tests. c The results of the cytotoxicity assays performed with iNKT 
cells derived from five donors at an E/T ratio of 5:1–15:1. p values were 
calculated with paired t tests. d The supernatants of cells incubated as 
in b were collected, and multiplex assays were performed in duplicate 
to determine the concentrations of cytotoxicity molecules. Cells were 
obtained from the same donors as in (b). Statistical analysis was per-
formed as in (b). The graphs with error bars show the standard devia-
tion. *p < 0.05. iso-NKT, iNKT cells stimulated with isotype control 
plus APC on day 0; PDL1-NKT, iNKT cells stimulated with PDL1-
blocked APCs on day 0; iso-cancer, cancer cells incubated with isotype 
control antibody before the cytotoxicity assay; PDL1-cancer, cancer 
cells incubated with anti-PDL1 antibody before the cytotoxicity assay; 
HD, healthy donor


























































































Fig. 6  Induction of NK cell-mediated cytotoxicity via activated iNKT 
cells. iNKT cells were purified and restimulated as in Fig. 3d. The 
supernatants were collected 6 h after restimulation, and residual anti-
bodies were magnetically removed with the addition of Dynabeads® 
Sheep anti-Mouse IgG. a NK cells were obtained from freshly iso-
lated PBMCs of a healthy donor by autoMACS Pro Separator negative 
selection using a NK isolation kit. NK cells were cultured in iNKT cell 
supernatants at a concentration of 7.5 × 105 cells/ml. After 24 h, the NK 
cells were collected, washed, counted, and seeded into 96-well plates 
with the cancer cell lines. The E/T ratio was 2:1 for K562 cancer cells 
and A549 cancer cells. b The degree of cytotoxicity at 4 h in quadrupli-
cate and c the levels of released cytotoxic molecules in duplicate were 
determined as in Fig. 5. d NK cells were seeded in the lower compart-
ment of a 0.4-μm-pore transwell plate. PDL1-blocked or isotype con-
trol APCs and iNKT cells were added at a ratio of 1:1:1 in either the 
upper compartment or the lower compartment. Twenty-four hours later, 
the cells from the lower chamber were collected and anti-CD3 beads 
were applied. Following negative selection via MACs, the CD3-negative 
cells were incubated with anti-CD56 beads and NK cells were positively 
selected. The cytotoxicity assays were performed as described above. 
The error bars represent the standard deviation. Isotype sup: NK cells 
cultured in supernatant derived from iNKT cells stimulated with isotype 
control antibody plus APCs, PDL1 sup: NK cells cultured in superna-
tant derived from iNKT cells stimulated with anti-PDL1 antibody plus 
APCs. Transwell: NK cells stimulated with iNKT cells and APCs in the 
upper compartment of a transwell system, cell–cell contact: NK cells 
stimulated with iNKT cells and APCs in the same compartment, sFasL: 
soluble Fas ligand. *p < 0.05 (multiple t tests)
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also found that blockade of both CD80 and PD-1 or PDL1 
resulted in higher levels of cytokine release from iNKT cells 
compared to PD-1 blockade alone. These results suggest 
that not only PD-1, but also CD80 can interact with PDL1, 
whose interaction negatively regulates iNKT cell function.
iNKT cells produce substantial amounts of both Th1 and 
Th2 cytokines upon stimulation, playing an important role 
in allergies, autoimmunity, infection, and antitumor immu-
nity. The exact mechanisms as to how the immune response 
is regulated toward the Th1 or Th2 direction are poorly 
understood. Different subsets of iNKT cells may produce 
different cytokines or different signals, and stimulants may 
lead to different responses after stimulation [34]. In the pre-
sent study, the blockade of PDL1 upon initial stimulation 
appeared to augment the release of cytotoxic molecules 
following tumor recognition. Additional blockade of PDL1 
expressed on tumor cell lines resulted in enhanced direct 
cytotoxicity of the stimulated iNKT cells. Since iNKT cells 
are reported to not directly exhibit antibody-dependent cel-
lular cytotoxicity (ADCC) [35], we concluded that PDL1 
blockade enhances cytotoxic functions of iNKT cells. In 
addition, we found that anti-PDL1 antibody only improved 
Th1 cytokine production, whereas PDL2 blockade 
appeared to increase IL-4 secretion. Signals transmitted via 
PDL1 and PDL2 may regulate human iNKT cells toward a 
Th1 or Th2 profile; this process may occur through the pro-
liferation of a certain subset of iNKT cells. This finding is 
similar to the observations noted in a murine model of air-
way hypersensitivity reaction (AHR). PDL2-deficient mice 
produce more IL-4 from iNKT cells, resulting in severe air-
way hypersensitivity. On the other hand, PDL1 deficiency 
or blockade results in an increase in IFNγ production and 
lower levels of AHR. According to these results, PDL1 and 
PDL2 appear to regulate mouse iNKT cell-mediated AHR 
in opposing directions [29]. Since both PDL1 and PDL2 
bind to PD-1 and suppress PI3 K activation, the mecha-
nisms underlying this difference may be due to the effects 
of other receptors, such as CD80 [36].
iNKT cell-derived cytokines, such as IFNγ and IL-2, are 
reported to activate cytotoxic T lymphocytes (CTL) and NK 
cells, which effectively abrogate the actions of tumor cells. 
The Th2 cytokine IL-4, on the other hand, suppresses CTL 
function [37] and stimulates a subset of B cells, thereby 
causing allergies. IL-10 is thought to induce regulatory T 
cells [34]. In the current study, supernatants derived from 
iNKT cells stimulated with PDL1-blocked APCs tended to 
enhance the effector function of NK cells. This may be the 
result of the increased ability of iNKT cells to produce Th1 
cytokines such as IL-2 and IFNγ. The ability to stimulate 
NK cells was further enhanced by direct cell–cell contact, 
which is probably the result of the expression of co-stim-
ulatory molecules on iNKT cells plus the effects of PDL1 
blockade.
In this study, it was possible to enhance IFNγ produc-
tion from patient-derived iNKT cells as well as healthy 
donors. A previous study on iNKT cell cytokine secretion 
in HIV patients revealed that the administration of anti-
PDL1 antibody could not improve the iNKT cell functions 
in HIV patients [23]. In the study, the authors stimulated 
whole PBMCs with αGalCer instead of purifying iNKT 
cells, which may have led to the difference in the results. 
Although our patients had stage IV lung cancer, there is 
also the possibility that there are differences in the levels 
of exhaustion and functional impairment between can-
cer and HIV patients. Further cytokine assays with an 
increased number of patient donors and the analysis of 
other inhibitory molecules should be performed to clar-
ify this point. It was not possible to perform cytotoxicity 
assays with patient-derived iNKT cells due to their low 
positivity and proliferation capacity. In spite of this limi-
tation, our results show that PDL1 blockade can reverse 
the impaired cytokine secretion of iNKT cells in cancer 
patients, which may lead to the enhanced activation of NK 
cells and T cells and the improved cytotoxicity of these 
cells.
Taken together, the addition of anti-PDL1 antibodies 
to αGalCer-pulsed APCs enhances the effector function 
of iNKT cells and also recruits other effector cells toward 
antitumor immunity. The finding that iNKT cells may be 
regulated to Th1 or Th2 phenotypes may also lead to the 
development of new strategies for controlling autoim-
munity, allergies, and transplant rejection. Further studies 
in vitro and in vivo are warranted to clarify the underlying 
mechanisms and test the feasibility of this new therapy.
Conclusion
Blockade of the PD-1/PDL1 axis in iNKT cells enhanced 
both direct and indirect antitumor immunity.
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